J.Safra Asset Management Corp Takes $940,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY

J.Safra Asset Management Corp acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,122 shares of the biopharmaceutical company’s stock, valued at approximately $940,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Flputnam Investment Management Co. purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $831,000. Global Retirement Partners LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $570,000. SCS Capital Management LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $34,784,000. Bank of New York Mellon Corp acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $148,128,000. Finally, Focus Partners Advisor Solutions LLC acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $341,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $228.65 on Monday. The company has a market capitalization of $30.60 billion, a P/E ratio of 42.50 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The stock has a 50-day simple moving average of $272.86 and a 200-day simple moving average of $301.02.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent research reports. Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st. HC Wainwright lowered their price objective on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research report on Friday, July 31st. JPMorgan Chase & Co. cut their target price on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Royal Bank Of Canada reduced their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $393.86.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.